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Philip W. Grubb 
Oxford University Press, 1999 
$80, 448 pages 
ISBN: 0198765207 
Reviewed by 
Michael J. Malinowski· 
THE COMMODITY OF INTELLECTUAL PROPERTY 
IN THE RISKY BUSlNESS OF LIFE SCIENCE 
uTo make a small fortune, invest a large fortune. "1 
Years before investors flocked to e-commerce start-up companies, investors 
were drawn to biotechnology? The modem biotechnology industry, much of 
which dates to the late l980s,3 was launched with an impassioned belief that small 
*Michael J. Malinowski is Associate Professor of Law, Widener University School of Law and 
author of BIOTECHNOLOGY: LAW, BUSINESS, AND REGULATION (1999 & Supp. 2000). This book 
review was submitted for publication in October 2000 and does not necessarily reflect all occurrences 
thereafter. 
l. Bruce Cohn, quoted in THE 2,548 BEST THINGS ANYBODY EVER SAID no. 283 (Robert Byrne 
ed., 1996). 
2. CYN'riDA ROBBINS-ROTH, FROM ALCHEMY TO IPO: THE BUSINESS OF BIOTECHNOLOGY 
183-97 (2000). 
3. See id at 7-9; Michael J. Malinowski & Maureen A. O'Rourke, A False Start? The Impact 
of Federal Policy on the Genotechnology Industry, 13 YALE J. ON REo. 163 (1996); ARTHUR 
KORNBERG: THE GoLDEN HELIX, INSIDE BIOTECH VENTURES 195-230 (1995). The beginning of the 
modem biotechnology industry often is traced to the founding of Genentech, Inc., in 1976. See 
KORNBERG, supra, at 195-202; ROBBINS-ROTH, supra note 2, at 13-30. 
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start-up companies could make breakthrough drugs in a fraction of the traditional 
time and at a fraction of the cost, shaming the multinational pharmaceutical 
behemoths and revolutionizing drug development and health care. 4 
The biotech industry has accomplished far more than sustaining itself. 5 
Expectations for biotech are being realized, albeit a decade or so later than many 
early investors projected. 6 There now are approximately 100 biotech drugs on the 
markee and hundreds of other applications, ranging from medical devices to 
biomaterials that are revolutionizing industrial processes. 8 With a flow of products 
entering commerce,9 maps of the human genome, 10 and innovative tools such as 
microarrays, biochips, and other infonnation technologies to accelerate making 
genotype-phenotype connections, 11 the biotech industry is entering a new cycle 
of"thinking big"-this time with the pharmaceutical industry by its side.12 
Given the pace of the development and commercialization of biotechnology, 
it is easy to be swept away by trends. In contrast, Patents for Chemicals, 
Pharmaceuticals and Biotechnology,13 published nearly two decades after the 
original edition, 14 embodies the grounded perspective of a seasoned European 
patent attorney. Patents is foremost a crisp, precise primer on patent criteria and 
procedure in the European Union (E.U.) and United States (U.S.) that is geared 
to practice. The book presents pragmatic infonnation on several levels, including 
the myriad considerations involved in developing effective global patent 
4. Cf Malinowski & O'Rourke, supra note 3, at 178 & n.77 (assumption that FDA would be 
quicker to approve technology based on "'natural' biologically derived molecules"). 
5. See Aris Persidis, Biotechnology in a Snapshot, 18 NATURE BIOTECHNOLOGY IT2 (2000) 
(Industry Trends Supplement). 
6. See generally ROBBINS·ROTH, supra note 2, at ix-xi; Juan Enriquez & Ray A .  Goldberg, 
Transforming Life, Transforming Business: The Life·Science Revolution, HARv. Bus. REv., Mar.-Apr. 
2000, at 96. 
7. See MICHAEL J. MALINOWSKI, BIOTECHNOLOGY: LAw, BUSINESS, AND REGULATION Fig. 3·2 
(1999 & Supp. 2000) (identifying biotech drugs approved through 1999). These include breakthrough 
drugs such as Avonex (beta interferon) to treat multiple sclerosis (see ROBBINS-ROTH, supra note 2, 
at 227 tbl. B. I) and Herceptin to treat breast cancer. See generally RoBERT BAZELL, HER·2: THE 
MAKING OF HERCEPTIN, A REVOLUTIONARY TREATMENT FOR BREAST CANCER (1998); Kenneth N. 
Gilpin, How Biotech Has Held On, and Its Prospects, N.Y. nMES, Nov. 26,2000, at 7. 
8. See generally Enriquez & Goldberg, supra note 6; RICHARD W. OLIVER, THE COMING 
BIOTECH AGE: THE BUSINESS OF BIOMATERIALS (2000); www.BJO.org (web site of the major 
biotechnology trade organization, the Biotechnology Industry Organization, which includes 
identification of product applications and approvals). 
9. See generally Enriquez & Goldberg, supra note 6; ROBBINS·ROTH, supra note 2; OLIVER, 
supra note 8. 
. 10. See WALL ST. J. EUROPE, 2000 WL-WSJE 21064884, June 27, 2000; Frederick Golden & Mtchael D. Lemonick, The Race Is Over, TIME, July 3, 2000, at 18-23. 
II. Michael Malinowski, Separating Predictive Genetic Testing from Snake Oil: Regulation, 
Liabilities, and Lost Opportunities, 41 JURIMETRICS J. 23 (2000); RoBtHNS-ROTH, supra note 2, at 
73-81. 
12. See Michael D. Lemonick, The Genome Is Mapped. Now What?, TIME, JULY 3, 2000, at 
24-29; Enriquez & Goldberg, supra note 6. 
13. See PHILIP W. GRUBB, PATENTS FOR CHEMICALS, PHARMACEUTICALS AND BIOTECHNOLOGY 
(1999) [hereinafter GRUBB). 
14. PlnLIP W. GRUBB, PATENTS FOR CHEMISTS (Oxford 1982); see a/so PHILIP W. GRUB B, 
PATENTS IN CHEMISTRY AND BIOTECHNOLOGY (1986). 
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prosecution strategies.:' It bl:�tns wtth an antruJudaon to the moJcrn patcru 
system, fol lowed by section� on p�llc:nt law itnJ procedure, the patentabaltl)' of 
inventions in specific techniGtl fields. pat enting 111 pradicc, iU\J the curnrnen:uaJ 
exploitation of patents. 
But Patents transcends the functional aspects of patenting in lite science. ·nu� 
author shares many thoughts, insights, and even some convictions on fundrunenlal 
issues in patent law and pol icy . (jiven the visionary nature of invention. o 
scholarly, thoughtful treatment of intellectua l property must do nothing less --it 
must look forward. In the life sciences. today · s intellectual property protection is 
the foundation for the next decade's product R&D.16 Patent:; en1bodics recogni­
tion that trends in science will affect the course of R&D and changes in industry 
and markets in life scicnce.17 The author appreciates the extent to which modem 
biotechnology is revolutionizing commercial life science, 11 and he emphasizes 
that patent protection is essential to investment in the costly endeavor of life 
science R&D. 19 
A theme running throughout Patents is that it is difficult to overestimate the 
impact of intellectual property on the existence of today's commercial life science 
industries. Arguably, the biotech industry has been as creative and resourceful in 
finance as it has been in research. 20 The industry has sustained and distinguished 
itself by approaching intellectual property as an investment commodity, 
pennitting investors to absorb extraordinary R&D risks. 21 By embracing the 
patentability of inventions in life science and making these inventions available 
15. GRUBB, supra note 13, at 70-86. 
16. Drug development spans 10-12 years and costs hundreds of millions of dollars. See 
PHARMACEtrriCAL RESEARCH AND MANuF ACIURERS OF AMERICA, 1998 INDUSTRY PROFILE 20, 
24-25 (1998). 
17. As stated by the author, 
In certain fields, however, development of a product necessarily takes very much longer than this [two 
to five years], because the approval of regulatory authorities has to be abtained before marketing is 
allowed. This is particularly the case for the pbannaceutical industry, since no new drug can be 
approved without extensive clinical testing to prove that it is safe and efficacious, and this process may 
easily take eight to 1 2 years or even more from the filing date of the original patent application. leaving 
an effective patient term of only eight to 12 years instead of approximately 17 for most other products 
GRUBB, supra note 13, at 146. 
18. See id at 225 ("Biotechnology has based a whole new industry, and patent protection for 
biotechnological inventions is of immense commercial importance."). 
19. See id at 225, 364. On the importance of intellectual property to the financial viability of 
the biotechnology industry, see James Donahue, Comment, Patenting of Human DNA Se­
quences-Jmplicationsfor Prenatal Genetic Testing, 36 BRANDEIS J. FAM. L. 267,282 (1997·1998) 
("Patent protection for DNA sequences is essential to secure continued private investment in 
biotechnology research."); Cliff D. Weston, Chilling of the Corn: Agricultural Technology in the Face 
of US. !'alent �� and the Cartagena Protocol •. 4 J. SM�L & EMERGING Bus. L. 377, 385 (2000) 
( observmg that biotechnology has been charactenzed as an mdustry whose wealth exists in its patents 
more than its products" and citing KENNETH J. BURCHFIEL, BIOTECHNOLOGY AND THE FEDERAL 
CIRCUIT§ 18.5 (1995)). 
. 20. See RoBBINS·ROTH, supra note 2, at 131-79; Stelios Papadopoulos, Business Models in B1otech, 18 NATURE BIOTECH. IT3-T4 (2000) (Industry Trends Supplement). 
21. See ROBBINS-ROTH, supra note 2, at 13 I -79. 
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for commercial applications via federal technology transfer policy, the U.S. has 
assumed a position of world leadership. 22 
Beyond recognizing the connection between intellectual property and 
investment, however, Patents is cautious. It touches on fundamental issues in 
patent policy and offers an invaluable, reflective, historical perspective, but it 
does not reach fully into the pressing policy issues encasing intellectual property 
protection in life science. 23 
In light of the connection between intellectual property and investment, a 
pragmatic treatment of life science patenting necessitates rigorous analysis of 
ongoing policy challenges to the patent regime. The stakes never have been 
higher. The intellectual property regime that is the basis for billions of dollars of 
investment in a number of industries is being challenged. The author's summary 
discussion of controversy over basic patent policy and practice in the U.S. does 
not fully capture the present state of affairs. Most notably, the maps of the human 
genome (near completion at the time Patents went into print) have rekindled 
challenges to patenting "products of nature" and accusations of over�patenting. 24 
Critics charge that the U.S. permits overly broad claims that do not reflect 
meaningful knowledge of the sequences being patented.25 Arguably, this 
22. See generally Michael J. Malinowski, Biotechnology in the USA: Responsive Regulation in 
the Life Science Industry, 2 INT 'L J. BIOTECH. 16 (2000). Any allegations that the industry has grossly 
overstated the nexus between recognition of intellectual property in life science invention and 
investment in life science R&D were put to rest on March 14, 2000. On that day, President Clinton 
and British Prime Minister Tony Blair issued a joint statement in support of public availability of all 
information about gene sequencing and the human genome. See Peter G. Gosselin & Paul Jacobs, 
Clinton, Blair to Back Access to Genetic Code, L.A. TIMES, Mar. 14, 2000, at C I. Pharmaceutical and 
biotech stocks plunged 21% over the next 48 hours. President Clinton quickly retreated from his 
position. See BIO Wins Clinton Clarification on Gene Patents, Market Recovery, 62 PINK SHEET, Apr. 
10, 2000, 2000 WL 8634334; Alex Berenson & Nicholas Wade, A Call for Sharing of Research 
Causes Gene Stocks to Plunge, N.Y. 'nMEs, Mar. 15, 2000, at AI, C16; E.S. Browning, NASDAQ 
Plunge Puts Index Down 6. 77% in 2 Days; Biotech Spur 200-Point Fall; Traders Shaken, WALL. ST. 
J., Mar. 15, 2000, at Cl; Andrew Pollack, Protecting a Favorable Image: Biotechnology Concerns 
in Quandary Over Drug Giants, N.Y. TIMES, Apr. 4, 2000, at Cl ("Remarks by President Clinton and 
Prime Minister Tony Blair of Britain in March that seemed to question patents on genes knocked $100 
billion in market value from the biotechnology industry in a day."). 
23. See, e.g., GRUBB, supra note 13, at 245-69 ("patenting of  genes, plants, and animals"), 
248-49 (patenting of ESTs), 249-51 (transgenic animals and plants), 256-60 (morality issues), 256 
(analysis of article 53(a), which "prohibits the grant of European patents for inventions the publication 
or exploitation of which would be contrary to (a) 'ordre public' or (b) morality, irrespective of whether 
or not the invention is patentable under Article 52"). For timely discussion of some of the most 
controversial issues in life science patenting, see Donna M. Gitter, Led Astray by the Moral Compass: 
Incorporating Morality into European Union Biotechnology Patent Law, 19 BERKELEY J. INT'L L. 
1 (2001); see also Sean D. Murphy, Biotechnology and International Law, 42 HARv. INT'L L.J. 47 
(2001). 
24. See GRUBB, supra note 13; Donahue, supra note 19, at 270-71. 
25. See Naomi Aoki, Patent Applications Booming in Biotech Strides in Human Genetic Code, 
Drive to Accrue Intellectual Capital Cited, BOSTON GLOBE, Aug. 30, 2000, at D 1. Controversy centers 
on patent inventions premised on DNA sequences known as expressed sequence tags (ESTs) and 
single nucleotides polymorphisms (SNPs), small fragments of genes that identify genetic variations 
associated with susceptibility to disease and responsiveness to drugs. See Molly A. Holman & Stephen 
R Munzer, Intellectual Property Rights in Genes and Gene Fragments: A Registration Solution for 
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con�oversy is �ug�enting th� influence of th� F�deral Ci�cuit over claim drafting 
a�d mterpret.
atton, toughenmg patent apphcatton reqUirements, narrowing the 
view of mfnngement, and generally weakening patent protection for biotech 
inventions. 27 
In addition to claim interpretation, maturation of the biotechnology industry 
is spurring a proliferation of patent infringement litigation, forcing the courts to 
fu�her scrutinize patent fundamentals in life science. 28 The patent infringement 
smts by Amgen and Genzyme against Transkaryotic29 are likely to mark the 
Expressed Sequence Tags, 85 IOWA L. REv. 735 (2000). Some companies, such as Human Genome 
Sciences and Celera Genomics, have been attempting to patent thousands of gene sequences. Because 
these companies know little about the function of the sequences, the practice raises questions under 
the utility standard. See Arti Kaur Rai, Regulating Scientific Research: Intellectual Property Rights 
and the Norms of Science, 94 Nw. U. L. REv. 77 (1999). 
26. According to Weston, supra note 19, at 395 (footnotes omitted): 
Courts have treated biotechnology as an unpredictable art. While the industry and technology advances, 
the court's estimation of predictability must naturally lag behind. Courts are reluctant to read claims and 
specifications broadly in fields of technology in which uncertainty inheres. The Federal Circuit has 
consistently placed biotechnology in the same unpredictable caste as chemistry and physiology. This 
practice alters the patent examiner's view of the inventor's application. Because the technology is 
unpredictable, greater particularity is required in invention disclosures. Frequently, examiners (or 
defendants in litigation) challenge the specification, claiming that it failed to describe the invention or 
to fully enable one skilled in the art to practice the invention. Enablement varies inversely with the 
unpredictability of the art. The inventor's assertions-that disputed steps in the specification are easily 
carried out by those skilled in the art-tend to be less willingly accepted by courts when assessing an 
unpredictable art. 
27. See id at 377. See, e.g., Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 234 FJd 
558 (Fed. Cir. 2000) (sharply limiting patent owner's access to the doctrine of equivalents); Utility 
Examination Guidelines, 66 Fed. Reg. 1092 (2001) (setting forth specific standards for the utility 
requirement); Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, PI, 
"Written Description" Requirement, 66 Fed. Reg. 1099 (2001). 
28. See, e.g., Festo Corp., 234 F.3d 558. Many industry insiders emphasize uncertainty: 
"The patent landscape is a minefield." Litigation can be expected to increase in the wake of the writ en 
description, doctrine of equivalents, and the patent caselaw. Many researchers have filed patent 
applications without a full understanding of the products of the genes isolated. The flurry of patent 
activity surrounding gene and DNA fragments prompted one industry analyst to remark that "812 
percent of the genome is covered" by patent applications. 
Weston, supra note 19, at 408 (quoting Tom Abate, Worms and Germs Bait Biotech's Hooks, S.F. 
CHRON., Jan. 12, 2000, at Dl (quoting Robert Levy, senior vice president for American Home 
Products, and Robert Olan, Chase H & Q analyst)) (footnotes omitted). 
29. The litigation is described in Ronald Rosenberg, TKT Tests Patent Law Limits, BosTON 
GLOBE, Dec. 20, 2000, at C6; Ronald Rosenberg, Genzyme Sues TKT Over Drug, BosTON GLOBE, 
July 26, 2000, at C I; Transkaryotic, Avent is Resume Defense Against Amgen in Trial, BOSTON GLOBE, 
July 6, 2000, at C7 (from Dow Jones); Jennifer Heldt Powell, Firm Hopes to Sell Despite Drug 
Lawsuit, BosTON HERALD, Aug. 4, 2000. Amgen filed suit against TKT and its partner Aventis SA 
in federal district court in Boston to stop them from selling Dynepo, an anemia treatment. According 
to Amgen, TKT is infringing on three key Amgen patents for Epogen (erythropoietin), the best-selling 
biotech drug ($4 billion in U.S. sales in 1999), which is used to stimulate red blood cell production. 
TKT claims that Amgen 's patents are overly broad, invalid, and fraudulently obtained. It contends that 
its approach to making Dynepo is distinguishable because it makes EPO using human cells rather than 
animal cells. (TKT uses a "gene activation" technology which turns on a switch inside human cells 
that activates the dormant gene responsible for making EPO, while Amgen makes the drug by cloning 
a human gene and splicing it into Chinese hamster ovary cells.) 
Similarly, Genzyme and TKT are competing to be the first to introduce a drug to treat Fabry's 
disease, a rare metabolic disorder that causes kidney failure and affects 2,000 to 4,000 men worldwide. 
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commencement of a phase of costly litigation resolving the scope of patent 
claims.30 
Such questions about the patentability of sequence data are being raised when 
reliance on the patent regime is at an all-time high. Historically, the pharmaceuti­
cal industry has invested 15 to 20% of total sales revenue on R&D compared with 
less than 4% for industry overall.31 In recent years, the investment in life science 
R&D has increased to well over 20%.32 The United States Patent and Trademark 
Office (PTO) is deluged with patent filings/3 particularly in genetics.34 
Even respecting the author's express decision to not predict how the patent 
system may change in the next decade,35 one cannot overlook that Patents does 
not fully address several trends already well underway. Perhaps reflecting major 
differences in intellectual property between the United States and European 
Union, Patents does not consider the complexity and intensity of technology 
transfer and licensing that has distinguished U.S. life science in recent years.36 
Although Patents includes a section on licensing and technology transfer,37 this 
d iscussion simply is not rigorous enough given the ongoing proliferation of 
academic-industry research alliances, the extent to which contemporary life 
science represents collaborations including licensing among competitors, 38 and 
Both companies have designed an enzyme replacement, alpha-galactosidase. Genzyme's preexisting 
patent is directed at methods of making the enzyme, and Genzyme's methodology, like Amgen's, is 
to use mammalian Chinese hamster ovaries. TKT has not revealed how it makes the enzyme. 
Genzyrne filed its action against TKT in federal district court in Wilmington, Delaware. 
30. "Patent applications take their cue from caselaw, with claim scope expanding and contracting 
to follow the prevailing regime. Under the current legal environment, inventors must submit narrower 
claims for their biotechnology inventions." Weston, supra note 19, at 409. More costly disputes are 
likely as competition increases. See Angela Cullen, Biotech Firms Expect an Increase in Patent Suits, 
WALL ST. J., Aug. 21,2000. For example, Gennany's MorphoSys AG incurred costs of$2.7 million 
to fight a high-profile patent dispute with the United Kingdom's Cambridge Antibody Technology 
Group. As a result, MorphoSys was forced to license the underlying technology from Genentech, Inc. 
31. GRUBB, supra note 13, at 367. 
32. PHARMACEUTICAL REsEARCHERS AND MANuFACTURERS OF AMERICA, ANNuAL REPORT 22 
(2000-2001), available at www.phrma.org. 
33. The PTO now issues 70% more patents-approximately 170,000 in 1999-than it did a 
decade ago. Peter Coy, The 21st Century Corporation, Bus. WEEK. Aug. 28, 2000, at 76; see also 
Aoki, supra note 25, at 01 (''The rise in patents can be explained, in part, by the unprecedented 
growth in the understanding of human biology and, more specifically, of the human genetic code. 
Scientists are making discoveries in record numbers. And more discoveries obviously mean more 
patents."). 
34. "Gene patent filings are growing even faster than patent applications for the biotech industry 
as a whole, said John Doll, who heads the patent office's biotechnology division. He estimates the 
number of gene applications will grow by one-third this year and expects the rate to accelerate in 
coming years." Id 
35. GRUBB, supra note 13, at v. 
36. The author commits less than 20 of the 448 pages in Patents to the patent aspects of 
licensing. See id. at 370-77, 395--407. 
3 7. Id at 395-407. 
38. See generally MALINOWSKI, supra note 7, at ch. 8; Malinowski & O'Rourke, supra note 3. 
Arguably, patents encourage licensing and collaboration among competitors and offer an alternative 
to secrecy. See, e.g., Aoki, supra note 25, at D1 (quoting Gregory Williams General Counsel for 
Biolabs Inc.). ' 
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the resulting complexities and implications. For example, Patents does not 
provide sufficient detail about U.S. federal technology transfer policy, the 
relevant legislation and regulations, and its aggressive implementation by both the 
public and private sectors. 39 Minimal attention is paid to the fact that academic­
industry research alliances have made the life science industry and its partners 
susceptible to a multitude of challenges from members of the academic 
community concerned about academic freedom. 40 Related issues that are 
addressed in passing if at all include: a dramatic shift in university policies to 
include equity interests in commercial endeavors;4t institutional and researcher 
conflicts of interest;42 the emergence of disputes between industry and academia 
arising out of these relationships;43 the fact that so many tools for doing cutting­
edge research have been developed by the private sector and are proprietary;44 and 
the role of organizations such as the Association of University Technology 
Managers and the Licensing Executives Society that facilitate information sharing 
among universities.45 
The author also does not probe the relationship between intellectual property 
and health care. Recent controversy over drug pricing in the United States has 
popularized challenges to the patent regime and its federal technology transfer 
counterpart.46 A public without national health care and exasperated by the cost 
39. For full identification and discussion of the related pieces of legislation and university 
application, see GENERAL ACCOUNTING OFFICE, REPORT TO CONGRESSIONAL COMMITTEES: 
TECHNOLOGY TRANSFER-ADMINISTRATION OF THE BAYH-DOLE ACT BY RESEARCH UNIVERSITIES 
GAO/RCED 98-126, 1998 WL 403207 (May 7, 1998). 
40. See generally Rai, supra note 25; Eyal Press & Jennifer Washburn, The Kept University, 285 
ATLANTIC MONTHLY, Mar. 2000, at 39-54. But see David Blumenthal et al., Participation of Life­
Science Faculty in Research Relationships with Industry, 335 NEW ENG. J. MEo. 1734 (1996) (data 
suggesting that industry providing up to two-thirds of overall funding may increase desired faculty 
behaviors without negatively affecting teaching and other obligations); Michael J. Malinowski & Nick 
Littlefield, Transformation of a Research Platform into Commercial Products: The Impact of United 
States Federal Policy on Biotechnology, in THE COMMERClALIZATION OF GENETIC RESEARCH: 
ETIDCAL, LEGAL, AND POLICY IsSUES (Timothy A. Caulfield & Bryn Williams-Jones eds., 1999). 
41. See, e.g., Guide to the Ownership, Distribution and Commercial Development of M.I.T. 
Technology (May 7, 2001 ), available atweb.mit.edu/afs/athena.mit.edu/org/t/tlo/www/guide.toc.html. 
42. See Conference Materials, Conference on Human Subject Protection and Financial Conflict 
oflnterest, Sponsored by HHS, NIH, CDC, ASPE, and FDA, Aug. 13-16, 2000, Bethesda, Maryland, 
available at orhp.osophs.dhhs.gov/coi/index.htm. 
43. For example, on May 30, 2000, Abbott Laboratories filed a lawsuit against Dr. Judah 
Folkman and Boston's Children's Hospital over inventorship, and Dr. Folkman filed counterclaims 
involving a substance that could starve cancerous tumors, which create their own blood vessels via 
angiogenesis. See Raja Mishra, Children's Countersues in Cancer Study Battle, BoSTON GLOBE, July 
19, 2000, at AI. In summer 2000, U.S. Senator Judd Gregg attempted to insert a 3 50-word amendment 
into an unrelated federal spending bill to enable Columbia University to obtain a patent extension 
estimated to generate $150 miJiion. See Ronald Rosenberg, Gregg Draws Ire Over Columbia Patent 
Move, BOSTON GLOBE, July 13, 2000, at AI. The patent at issue had been licensed by 33 companies, 
including biotech leaders Amgen, Biogeo, and Genzyme. !d. 
44. See generally Malinowski, supra note 22. 
45. See, e.g., www.autm.net; www.les.org. 
46. See Campaign 2000 Third Party Candidates: Site Compiles Health Care Views, American 
Political Network, American Health Line, Sept. 26, 2000 (challenges of Ralph Nader and Green 
Party). 
. 
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of health insurance and drug prices is demanding price controls on the ground that 
pharmaceutical companies have benefitted from the billions of dollars of 
government investment in basic research.47 
Although Patents shies away from predicting how the patent system will look 
in ten or twelve years, it does predict that the book will be outdated by that time. 48 
In fact, several aspects of Patents already invite change. First, the pragmatic 
treatment of patenting in Europe and the U.S. in Parts I and II is accompanied by 
separate individual chapters addressing chemical inventions, pharmaceutical 
inventions, biotechnological inventions, patenting of genes, plants, and animals, 
and software-related inventions. These classifications already are somewhat 
forced. These technical fields are being integrated and influenced by fields such 
as combinatorial chemistry that are vital to both the pharmaceutical and 
biotechnology industries.49 With the R&D distinction between the phannaceutical 
and biotechnology industries becoming increasingly forced, "Patents in Life 
Science" will be a suitable title for the author's next edition. 
Change also is warranted in the treatment of information technology. In 
Patents, the author includes a somewhat gratuitous discussion of software. 50 In 
fact, there already are an abundance of natural bridges between information 
technology and life science, including bioinfonnatics, biochips, microassays, data 
mining, proteomics, pharmacogenomics, and pharmacogenetics, some of which 
are mentioned by the author in passing. 51 The explosive potential of informatics 
is a driving force in life science R&D, 52 and the full impact of this collection of 
technologies on life science R&D by the next edition of Patents truly is beyond 
prediction. 
These reservations aside, Patents is exactly what it proposes to be-a 
pragmatic primer on life science patenting in Europe and the United States that 
encompasses a critical mass of clear and thoughtfully presented information on 
the topic. Like the editions that came before, Patents is an �valuable resource for 
reference as well as strategy and study. Given the increased globalization of life 
science in recent years, the European perspective and sensitivity to global issues 
embodied in Patents are particularly valuable for U.S. patent attorneys and 
scholars. The author should be congratulated on making yet another ambitious 
contribution to this rapidly evolving and increasingly international field of law, 
science, and business. 
47. See id Moreover, prices are exceeding expectations. See Robert Pear, Health Costs 
Underestimated, Experts Say Cost of Medical Care Is Underestimated, N.Y. TIMES, Nov. 30, 2000, 
at AI. 
48. GRUBB, supra note 13, at v. . 
49. See generally Persidis, supra note 5; Enriquez & Goldberg, supra note 6. 
50. �e G
.
RuB.B ,  supra note: 13, .at 261 (''A chapter on software-related inventions may appear to be a dtgresston m a book pnmanly concerned with the technical fields of chemistry pharma-
ceuticals, and biotechnology."). 
' 
51. For discussion of these and other innovative technologies, see Persidis, supra note 5, at 
IT31-T47; RoBBINS-ROTH, supra note 2, at 73-81 (discussing biochips and microarrays). 
52. See Malinowski, supra note 11, at 26, 32-33. 
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